Abstract:Abstract Background Aberrant changes in epigenetic mechanisms such as histone modifications play an important role in cancer progression. PRMT1 which triggers asymmetric dimethylation of histone H4 on arginine 3 (H4R3me2a) is upregulated in human colorectal cancer (CRC) and is essential for cell proliferation. However, how this dysregulated modification might contribute to malignant transitions of CRC remains poorly understood. Methods In this study, we integrated biochemical assays including protein interaction studies and chromatin immunoprecipitation (ChIP), cellular analysis including cell viability, proliferation, colony formation, and migration assays, clinical sample analysis, microarray experiments, and ChIP-Seq data to investigate the potential genomic recognition pattern of H4R3me2s in CRC cells and its effect on CRC progression. Results We show that PRMT1 and SMARCA4, an ATPase subunit of the SWI/SNF chromatin remodeling complex, act cooperatively to promote colorectal cancer (CRC) progression. We find that SMARCA4 is a novel effector molecule of PRMT1-mediated H4R3me2a. Mechanistically, we show that H4R3me2a directly recruited SMARCA4 to promote the proliferative, colony-formative, and migratory abilities of CRC cells by enhancing EGFR signaling. We found that EGFR and TNS4 were major direct downstream transcriptional targets of PRMT1 and SMARCA4 in colon cells, and acted in a PRMT1 methyltransferase activity-dependent manner to promote CRC cell proliferation. In vivo, knockdown or inhibition of PRMT1 profoundly attenuated the growth of CRC cells in the C57BL/6 J-Apc Min/+ CRC mice model. Importantly, elevated expression of PRMT1 or SMARCA4 in CRC patients were positively correlated with expression of EGFR and TNS4, and CRC patients had shorter overall survival. These findings reveal a critical interplay between epigenetic and transcriptional control during CRC progression, suggesting that SMARCA4 is a novel key epigenetic modulator of CRC. Our findings thus highlight PRMT1/SMARCA4 inhibition as a potential therapeutic intervention strategy for CRC. Conclusion PRMT1-mediated H4R3me2a recruits SMARCA4, which promotes colorectal cancer progression by enhancing EGFR signaling.

Targeting SMYD2 inhibits angiogenesis and increases the efficiency of apatinib by suppressing EGFL7 in colorectal cancer

ANGPTL1 Attenuates Colorectal Cancer Metastasis by Up-Regulating Microrna-138

SMYD2 Suppresses APC2 Expression to Activate the Wnt/β-catenin Pathway and Promotes Epithelial-Mesenchymal Transition in Colorectal Cancer.

Therapeutic Potential of Apatinib Against Colorectal Cancer by Inhibiting VEGFR2-Mediated Angiogenesis and -Catenin Signaling

SMYD2 targets RIPK1 and restricts TNF-induced apoptosis and necroptosis to support colon tumor growth

Synergistic Antitumor Effects of Cmet Inhibitor in Combination with Anti-Vegf in Colorectal Cancer Patient-Derived Xenograft Models

AAMP Promotes Colorectal Cancer Metastasis by Suppressing SMURF2-mediated Ubiquitination and Degradation of RhoA

Knock Down of HMGA2 Suppresses Colorectal Cancer Progression Through Inhibiting Angiogenesis Via Compromising VEGFR2 Signaling in HUVECs

Targeting SMYD2 Inhibits Prostate Cancer Cell Growth by Regulating C-Myc Signaling.

Targeting PELP1 Attenuates Angiogenesis and Enhances Chemotherapy Efficiency in Colorectal Cancer

Circ0106714 Inhibits Tumorigenesis of Colorectal Cancer by Sponging Mir‐942‐5p and Releasing DLG2 Via Hippo‐YAP Signaling

Endothelial deletion of SHP2 suppresses tumor angiogenesis and promotes vascular normalization

Apatinib Enhanced Anti-Pd-1 Therapy for Colon Cancer in Mice Via Promoting PD-L1 Expression.

Studies of the Efficacy of Low-Dose Apatinib Monotherapy as Third-Line Treatment in Patients with Metastatic Colorectal Cancer and Apatinib's Novel Anticancer Effect by Inhibiting Tumor-Derived Exosome Secretion

MYSM1 inhibits human colorectal cancer tumorigenesis by activating miR-200 family members/CDH1 and blocking PI3K/AKT signaling

APC coordinates GSK3 phosphorylation of SETD8 to suppress colorectal cancer

DMDRMR Promotes Angiogenesis Via Antagonizing DAB2IP in Clear Cell Renal Cell Carcinoma

PRMT1-mediated H4R3me2a recruits SMARCA4 to promote colorectal cancer progression by enhancing EGFR signaling

PCYT2 Inhibits Epithelial-to-mesenchymal Transition in Colorectal Cancer by Elevating YAP1 Phosphorylation

KRAS mutation-driven angiopoietin 2 bestows anti-VEGF resistance in epithelial carcinomas

Abstract 23: Microrna302-367 Sphingosine 1 Phosphate Receptor 1 Pathway Prevents Tumor Growth Via Restricting Angiogenesis and Enhancing Vascular Stability